Storming Media: Pentagon Reports and DocumentsPentagon Reports: Fast. Definitive. Complete.     
New Account »
Forgot Password?
Advanced Search »
MedicineAnatomy and Physiology

VP35 Knockdown Inhibits Ebola Virus Amplification and Protects Against Lethal Infection in Mice

Authors: Sven Enterlein; Kelly L. Warfield; Dana L. Swenson; David A. Stein; Jeffrey L. Smith; C. S. Gamble; Andrew D. Kroeker; Patrick L. Iversen; Sina Bavari; Elke Muehlberger; PHILIPPS UNIV MARBURG (GERMANY)
Abstract:
Phosphorodiamidate morpholino oligomers (PMO) are a class of uncharged single-stranded DNA analogs modified such that each subunit includes a phosphorodiamidate linkage and morpholine ring. PMO antisense agents have been reported to effectively interfere with the replication of several positive-strand RNA viruses in cell culture. The filoviruses, Marburg virus and Ebola virus (EBOV), are negative-strand RNA viruses that cause up to 90% lethality in human outbreaks. There is currently no commercially available vaccine or efficacious therapeutic for any filovirus. In this study, PMO conjugated to arginine-rich cell-penetrating peptide (P-PMO) and nonconjugated PMO were assayed for the ability to inhibit EBOV infection in cell culture and in a mouse model of lethal EBOV infection. A 22-mer P-PMO designed to base pair with the translation start site region of EBOV VP35 positive-sense RNA generated sequence-specific and time- and dose-dependent inhibition of EBOV amplification in cell culture. The same oligomer provided complete protection to mice when administered before or after an otherwise lethal infection of EBOV. A corresponding nonconjugated PMO, as well as nonconjugated truncated versions of 16 and 19 base residues, provided length-dependent protection to mice when administered prophylactically. Together, these data suggest that antisense PMO and P-PMO have the potential to control EBOV infection and are promising therapeutic candidates.

Limitations: APPROVED FOR PUBLIC RELEASE
Description: Journal article
Pages: 12
Report Date: MAR 2006
Report Number: A616344
Keywords relating to this report:
*EBOLA VIRUS
*INFECTIOUS DISEASES
*LETHALITY
*VACCINES
AMPLIFICATION
ANALOGS
ANATOMICAL MODELS
ANTISENSE THERAPY
ARBOVIRUSES
CELLS_BIOLOGY_
CHEMICAL AGENTS
CULTURES_BIOLOGY_
DEOXYRIBONUCLEIC ACIDS
DOSAGE
MICE
MORPHOLINE
PROTECTION
RINGS
THERAPY
VIRUSES
Email This Abstract